---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-073386"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:45:23.313173+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kymera reports FY2025 net loss $311M; cash $1.6B; STAT6 and IRF5 trials advancing

## Summary
- Cash and investments of $1.6B as of Dec 31, 2025, providing runway into 2029.
- KT-621 (STAT6) Phase 2b in atopic dermatitis (enrollment ongoing) and asthma (dosing started); data expected mid- and late-2027.
- KT-579 (IRF5) Phase 1 healthy volunteer trial dosed; data expected in 2H26.
- Appointed Dr. Neil Graham as Chief Development Officer; he led dupilumab development at Regeneron.
- FY2025 collaboration revenue $39.2M, R&D expense $316.6M, net loss $311.4M (vs. $223.9M in FY2024).

## SEC filing metadata
- accession: 0001193125-26-073386
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073386/0001193125-26-073386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312526073386/kymr-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-073386
- JSON: https://secwatch.observer/filing/0001193125-26-073386.json
- Plain text: https://secwatch.observer/filing/0001193125-26-073386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.